OGDHL promotes prostate cancer progression and regulates neuroendocrine marker expression and nucleotide abundance

By afschroeder • January 28, 2026

Bernard MJ, Gallardo A, Ruiz A, Diaz JA, Nunley NM, Dove RN, Zhang S, Lee E, Heering KY, Varuzhanyan G, Bopardikar S, Hashimoto T, Agrawal R, Smith CM, Wilde BR, Matulionis N, Richards HM, Lee SCS, Sharifi MN, Lang JM, Zhao SG, Witte ON, Haffner MC, Shackelford DB, Boutros PC, Christofk HR, Goldstein AS. OGDHL promotes prostate cancer progression and regulates neuroendocrine marker expression and nucleotide abundance. Mol Cancer Res. 2026 Jan 27. doi: 10.1158/1541-7786.MCR-25-0913. Epub ahead of print. PMID: 41591383.

Tags: Publications, Pulmonary, Critical Care & Sleep Medicine

Assessing the Reliability of Telehealth Geriatric Screening in Older Adults Undergoing Surgery

Canales C, Ivanson HC, Brooks R, Smith J, Boulos NM, Grogan T, Singh S, Sarkisian C, Cannesson M, Whittington R. Assessing the Reliability of Telehealth[...]

A Comparison of Prostate Cancer Incidence and Mortality Rates in the Veterans Affairs Healthcare system and the Surveillance, Epidemiology, and End Results Program

Bailey AV, Frochen S, Kwan L, Siavoshi M, Haroldsen CL, Shelton JB, Rose B, Maxwell KN, Nickols NG, Yamoah K, Rebbeck TR, Schoen MW, Rettig[...]

Target Versus Below-Target Dose ACE Inhibitors in U.S. Veterans with HFpEF: Differential Outcomes by CKD Status

Lu F, Ahmed AA, Zhang S, Raman VK, Patel SS, Vargas JD, Fonarow GC, Heidenreich PA, Cleland JGF, Anker SD, Böhm M, Metra M, Zile[...]